Status:
COMPLETED
Pergolide Treatment and Valvular Heart Disease
Lead Sponsor:
Århus Amt
Conditions:
Heart Valve Diseases
Parkinson's Disease
Eligibility:
All Genders
Brief Summary
In a blinded echocardiographic study we investigate the frequency of valvular abnormalities in a group of Parkinson patients treated with either ergot derived dopamine agonists (pergolide and cabergol...
Detailed Description
Some case reports and a single study, which included 78 Parkinson patients, has found a correlation between treatment with the ergotamine derivative dopamine agonists (pergolide) and restrictive valvu...
Eligibility Criteria
Inclusion
- Parkinson patients who in the last year has been treated minimum 6 months with either ergotamine derivative or non-ergotamine derivative dopamine agonists (the latter included as controls)
- Informed contests
Exclusion
- Control patients will be excluded if the have been treated with ergotamine derivates in the last 12 months or if the prior to that have had ergotamine derivates for more than 6 months
- Patients with known valvular heart disease prior to the diagnosis of Parkinson
Key Trial Info
Start Date :
March 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT00234364
Start Date
March 1 2005
End Date
September 1 2007
Last Update
September 20 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Skejby Hospital
Aarhus, Aahus N, Denmark, 8200